Tracer library / [225Ac]Ac-Pep-1L
[225Ac]Ac-Pep-1L
Also written as [Ac-225]Pep-1L
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated peptide (Pep-1L)
- Target / mechanism
- IL13RA2 (interleukin 13 receptor alpha 2) targeting peptide PMID 28562337
- Clinical application
- Alpha particle radionuclide therapy for glioblastoma via convection-enhanced delivery PMID 28562337
- Theranostic pair
- [64Cu]Pep-1L
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >95% | DOTA-Pep-1L CPC Scientific, San Jose, CA | 28562337 2017 Oncotarget the prepared DOTA-Pep-1L (CPC-scientific, San Jose, CA) was incubated with Ac-225 at 70°C for 50 minutes |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- CPC Scientific
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [225Ac]Ac-Pep-1L, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 28562337. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28562337: 'the prepared DOTA-Pep-1L (CPC-scientific, San Jose, CA)'.